Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29625786 | 1.00 | MEN1 (0.50) | MEN1KMT2AHTTKDM4ETSHR | |
| SCHEMBL24953240 | 0.83 | KDM4E (0.55) | MEN1KMT2AHTTKDM4ETSHR | |
| SCHEMBL29625751 | 0.83 | KDM4E (0.55) | MEN1KMT2AHTTKDM4ETSHR | |
| SCHEMBL28727071 | 0.80 | KMT2A (0.52) | MEN1KMT2AHTTTSHRALDH1A1 | |
| SCHEMBL28727021 | 0.72 | NPBWR1 (0.54) | MEN1KMT2AHTTTSHRALDH1A1 | |
| SCHEMBL8293061 | 0.71 | PLA2G2A (0.47) | MEN1KMT2ATSHRALDH1A1LMNA | |
| SCHEMBL29620186 | 0.70 | MAPT (0.58) | MEN1KMT2AHTTKDM4EMAPT | |
| SCHEMBL702988 | 0.70 | MAPT (0.58) | MEN1KMT2AHTTKDM4EMAPT | |
| SCHEMBL19766698 | 0.70 | MAPT (0.62) | MEN1KMT2AMAPTHSD17B10 | |
| SCHEMBL6797257 | 0.69 | KMT2A (0.79) | MEN1KMT2AHTTKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | SHANGHAI EAST HOSPITAL (CN) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | CACNA1F, CACNA1S, CACNA1D | MEN1 2638/4885KMT2A 3777/4885HTT 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.